Basis: Four-quarter free cash flow / FMP quote market capitalization × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The free cash flow yield is N/A as of 2026-10-06T19:53:58.231Z.
Calculation as of: 2026-10-06T19:53:58.231Z.
Quote observation: 2026-10-06T19:50:20.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 30661e2ab8049c45f8bd89fe5e3b6011ccda1def8f6e1910b04e1fe893bb4686
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FREE CASH FLOW YIELD
N/A
Sol-Gel Technologies Ltd.
Market Cap
$241.48M
Free Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$241.68M
Free Cash Flow Yield
N/A
TTM Avg
12.33%
3Y Avg
12.33%
5Y Avg
12.33%
Market Cap
$241.94M
Free Cash Flow Yield
N/A
TTM Avg
1.67%
3Y Avg
1.64%
5Y Avg
2.28%
Market Cap
$239.92M
Free Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$238.57M
Free Cash Flow Yield
4.81%
TTM Avg
5.58%
3Y Avg
6.49%
5Y Avg
6.20%
Market Cap
$238.38M
Free Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$247.56M
Free Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$236.17M
Free Cash Flow Yield
17.01%
TTM Avg
15.02%
3Y Avg
15.02%
5Y Avg
15.02%
| NAME | MARKET CAP | FREE CASH FLOW YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Sol-Gel Technologies Ltd. (SLGL) | $241.48M | N/A | N/A | N/A | N/A |
| Q32 Bio Inc. (QTTB)vs › | $241.68M | N/A | 12.33% | 12.33% | 12.33% |
| Lifecore Biomedical, Inc. (LFCR)vs › | $241.94M | N/A | 1.67% | 1.64% | 2.28% |
| Century Therapeutics, Inc. (IPSC)vs › | $239.92M | N/A | N/A | N/A | N/A |
| High Tide Inc. (HITI)vs › | $238.57M | 4.81% | 5.58% | 6.49% | 6.20% |
| Quantum-Si incorporated (QSI)vs › | $238.38M | N/A | N/A | N/A | N/A |
| Invivyd, Inc. (IVVD)vs › | $236.69M | N/A | N/A | N/A | N/A |
| CAMP4 Therapeutics Corporation (CAMP)vs › | $247.56M | N/A | N/A | N/A | N/A |
| Akebia Therapeutics, Inc. (AKBA)vs › | $236.17M | 17.01% | 15.02% | 15.02% | 15.02% |
| Galectin Therapeutics Inc. (GALT)vs › | $248.14M | N/A | N/A | N/A | N/A |
FCF Yield
N/A
Earnings Yield
N/A
Dividend Yield
N/A
Formula: FCF Yield = (Free Cash Flow / Market Cap) × 100
How FCF Yield is used:
FCF vs earnings: Differences between FCF yield and earnings yield can reflect capital expenditures, working capital changes, and other non-cash accounting items.
FCF Yield measures free cash flow relative to market capitalization. It compares cash generation after capital expenditures with the equity value of the company.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
